<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901338</url>
  </required_header>
  <id_info>
    <org_study_id>Haemoadsorption ECMO</org_study_id>
    <nct_id>NCT04901338</nct_id>
  </id_info>
  <brief_title>Cytokine Hemoadsorption in ECMO Patients</brief_title>
  <official_title>Cytokine Hemoadsorption in ECMO Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytokine hemoadsorption is a novel therapy used to improve outcome in critically ill patients&#xD;
      with a dysregulated cytokine response and hemodynamic instability. Patients on extracorporeal&#xD;
      membraneous oxygenation (ECMO) often develop severe systemic inflammatory response syndrome&#xD;
      (SIRS). Cytokine removal using different types of hemoadsorption devices is believed to block&#xD;
      the vicious circle of inflammation dysregulation when other basic therapeutic measures fail.&#xD;
      To date there are very limited reports on ECMO and cytokine hemoadsorption combination&#xD;
      therapy. The aim of this retrospective study is to evaluate feasibility and effectiveness of&#xD;
      hemoadsorption in veno-arterial and veno-venous ECMO patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Haemodynamic stabilization</measure>
    <time_frame>Within 12 hours after hemoadsorption</time_frame>
    <description>Decreased need for vasopressors according to vasoactive-inotropic score and increase in mean arterial pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactate, interleukin-6, C-reactive protein and procalcitonin clearance</measure>
    <time_frame>Within 12 hours after hemoadsorption</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weaning from ECMO</measure>
    <time_frame>from day of ECMO-implant for every 24 hours until date of weaning or death, whichever came first, assessed up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>from day of ICU-admission for every 24 hours until date of discharge or death, whichever came first, assessed up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>from day of hospital admission until date of discharge or death, whichever came first, assessed up to 90 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>SIRS</condition>
  <condition>Cytokine Storm</condition>
  <condition>Cardiogenic Shock</condition>
  <condition>Cardiac Arrest</condition>
  <condition>Septic Shock</condition>
  <condition>ARDS, Human</condition>
  <arm_group>
    <arm_group_label>Veno-arterial ECMO patients</arm_group_label>
    <description>Patients with severe SIRS post extracorporeal cardiopulmonary resuscitation (ECPR) or accompanying cardiogenic shock who were treated with hemoadsorption.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Veno-venous ECMO patients</arm_group_label>
    <description>Patients with refractory septic shock on VV ECMO who were treated with hemoadsorption.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients on VA ECMO or VV ECMO treated with hemoadsorption&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  VA/VV ECMO&#xD;
&#xD;
          -  hemoadsorption&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no additional exclusion criteria after being eligible for ECMO&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Jernej Berden</investigator_full_name>
    <investigator_title>Jernej Berden, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Hemoadsorption</keyword>
  <keyword>ECMO</keyword>
  <keyword>SIRS</keyword>
  <keyword>ARDS</keyword>
  <keyword>Post-resuscitation syndrome</keyword>
  <keyword>ECPR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Cytokine Release Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

